logo
ONE BRAND: Made to Launch - A Decade in the Making – Uniting Humanity, Raising Impact, and Transforming Earth

ONE BRAND: Made to Launch - A Decade in the Making – Uniting Humanity, Raising Impact, and Transforming Earth

Exclusive Beta 2.5 Launch Unites Limited-Edition Luxury, Philanthropy, and Community Empowerment, Pioneering a New Era of Heart-Centered Impact.
'At this unique and historic turning point in Earth and humanity's timeline, it is now more important than ever for ONE to remind and unite us all as one. We are one.' — President Reginald Trent, Co-Founder, ONE BRAND
LOS ANGELES, CA, UNITED STATES, March 16, 2025 / EINPresswire.com / -- ONE BRAND, a revolutionary force in luxury fashion and social impact, today announces an exciting fundraising campaign that invites supporters, donors, and investors to join a once-in-a-lifetime movement. Born from a decade-long vision of unity and impact, ONE BRAND is dedicated to reminding humanity of its deep connection to self, one another, and our planet—all while giving away 50% of every sales transaction to the charity of each customer's choice.
A Journey Fueled by Destiny and Determination
The story of ONE BRAND is as inspiring as it is transformative. In 2017, on the auspicious date of 11/11, the founders—esteemed designers and trailblazers behind the iconic family brands BRAGGS® and Cartilli® —met and forged a partnership that would forever change their lives. With vast experience in online business, financial management, and creative design, they brought together their passions and expertise to birth ONE BRAND—a labor of love built while juggling multiple 9-to-5 jobs, overcoming obstacles, and daring to dream big.
'11/11 changed everything,' reflects Reginald Trent, Founder and CEO of ONE BRAND. 'Meeting my partner Ebru on November 11 was a pivotal turning point. It signaled the merging of creative forces and the alignment of our destinies to build something that goes beyond profit and self toward something more. We are here to raise humanity by raising awareness—reconnecting us to our true authentic selves, one another and our shared planet by reminding the world that we are one.'
A Mission Beyond Fashion
At its core, ONE BRAND is not just a clothing company; it is awareness with choice. ONE's mission is to unite, inspire, and empower. In a world where less than 2% of funding reaches minority and female-led investors, ONE BRAND boldly bypasses traditional venture capital. Instead, we choose a path where planet and people come before the profit narrative in the world of venture capital. Every transaction is a chance to give back—a testament to the belief that as we desire for ourselves, so too should we desire the same for others.
Through our innovative fundraising campaign on Fundly, we invite you to become a founding member of this transformative journey. Your support will help ONE BRAND scale its mission, achieve a projected income of $250,000 per month, and amplify our global impact.
Transformative Partnerships and Unprecedented Reach
In our quest to make a lasting difference, ONE BRAND has recently partnered with Change at Getchange.io—recognized as the NBA's official charity partner. This strategic alliance opens the door to over 1.3 million charities and nonprofits, ensuring that every donor's gift is matched with a cause close to their heart. With this partnership, our fundraising initiative is not just about raising funds—it's about connecting communities with meaningful opportunities to give back and celebrate unity.
A Founding Fundraising Campaign: Tiered Giving Levels
ONE BRAND's fundraising campaign is thoughtfully designed with tiered giving levels that honor each supporter's contribution:
* $1,111 – The Believer (Founding Family Member): 1-Year Family VIP Membership (50% off all products, plus invitation-only events, valued at $2,222) – 1-Year Area One Journeys Membership (50% off all products) – Digital Thank You and Founding Family Member Designation
* $5,555 – Hands of Grace: All Believer Tier benefits – 2-Year Family VIP-Priority Membership (including free shipping, priority perks, and exclusive events ) – 2-Year Area One Journeys Membership (50% off ceremonies and products) – $1,000 Store Card and Early Apparel Access
* $55,555 – FAMILY FOR LIFE: Lifetime Family VIP Priority Membership – $5,000 Store Card – Early Apparel Access and Invitation to Private Family Events
* $250,250 – THE ONE: $10,000 Store Card – 1 Private Personalized Couture Collection Design (custom tailored, with development value TBD) – A 7-Night Area One Journey Stay for you and 3 guests – Signature Recognition on the Founder Wall – Exclusive Investment Opportunities
Each tier is crafted to not only reward our donors but also to weave them into the fabric of our community—a community that truly embodies our belief that: We Are One.
A Call to Unity and Transformation
ONE BRAND is more than a business—it is a beacon of hope, a call to action for all those who believe in a future defined by unity, generosity, and high-vibe living. Our journey, marked by perseverance and fueled by passion, invites you to join us in elevating humanity. With every donation, every purchase, you help rewrite the narrative of what it means to be truly successful—a narrative where the well-being of our planet and its people comes first.
As we step into a new era of full-time leadership and strategic growth, ONE BRAND remains steadfast in its mission: to reconnect humanity to itself, to one another, and to the Earth. We invite you to be a part of this historic movement. Let's raise awareness, create lasting change, and celebrate the collective power of our unified diversity.
Are You ONE?
If you believe that we are all one, if you embrace peace, unity, and the power of giving back, then you are ONE. Join us in this extraordinary journey. Together, we can make an impact that transcends time and borders.
https://fundly.com/one-brand-made-to-launch.
Ebru Cartilli
BRAGGS FAMILY GROUP
+1 213-588-1143
Other
Legal Disclaimer:
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BZI® Announces Its Ranking as #1 in the 'Construction Top Workplaces 2025' Award for U.S. Companies with 500-999 Employees
BZI® Announces Its Ranking as #1 in the 'Construction Top Workplaces 2025' Award for U.S. Companies with 500-999 Employees

Business Wire

time13 minutes ago

  • Business Wire

BZI® Announces Its Ranking as #1 in the 'Construction Top Workplaces 2025' Award for U.S. Companies with 500-999 Employees

KANARRAVILLE, Utah--(BUSINESS WIRE)--BZI® ( a leading steel and construction company nationally recognized for transformative innovations in its industries, announced today that the company has been ranked #1 in the 'Construction Top Workplaces 2025' Award for U.S. companies with 500-999 employees. The company is one of a few specialty steel erector businesses recognized out of 137 construction organizations from across the nation. Top Workplaces celebrates outstanding companies that listen to their people and put them at the center of decisions to build cultures where people and performance thrive. The lists are chosen based solely on employee feedback gathered through an employee engagement survey, issued by Energage. Results are calculated by comparing the survey's research-based statements. 'BZI has created a people-first culture where employees can thrive,' said Bob Helbig, media partnerships director at Energage. 'This award can't be bought; it's earned through employee feedback. The message from employees is clear: BZI is a leader in the industry for unleashing the power of people to accomplish great things.' 'Knowing the feedback provided by our BZI team members determined our #1 national ranking among construction companies makes this recognition even more rewarding and meaningful,' said James Barlow, CEO of BZI. 'It is a core value at BZI to foster a rewarding environment that brings high-value opportunities to our teams and their families. We are honored to be listed alongside other companies who care about building and providing outstanding cultures.' For more information about BZI, visit email office@ or call 888.509.2280. About BZI Considered one of the top steel and construction organizations, the BZI® group of companies headquartered in Kanarraville, Utah, operates through three primary organizations: Building Zone Industries, LLC is responsible for steel erection, while BZI Steel, LLC specializes in steel fabrication. Innovatech®, LLC specializes in designing, engineering, and manufacturing innovative construction equipment and processes to enhance efficiency and safety on the job. BZI's partnership with the one-of-a-kind SteelTech Academy™ provides training, certifications and continuing education to all its team members. An exclusive technical, safety, vocational, and leadership training center, the academy provides training in OSHA (10) and (30) certifications, equipment operations, fall protection, and industry-specific welding certifications. Since 2021, SteelTech Academy has issued thousands of certifications across these disciplines and consistently logs over 30,000 student contact hours annually. As part of this expansive training curriculum, the academy also offers a Department of Labor certified Apprenticeship Program, helping to shape relevant skills and advance careers for those wanting to pursue construction as a vocation. The company continues to receive numerous industry awards for its exceptional performance and contributions to its industries. The company has been the recipient of: Inc. Best in Business 2024 for Construction: BZI Innovation Park USA Today's Top Workplaces (Second year – Ranked #11 in the nation for midsize companies in 2025) Utah Business Fast 50 (#12 ranking) Top Workplaces Construction Industry Award Salt Lake City Tribune Top Workplaces for two years (#5 ranking in 2024) One Utah Summit "Rural Rockstar" Award presented by Utah Governor Cox Best Employer by Cedar City Chamber of Commerce CEO of the Year by Cedar City Chamber of Commerce CEO of the Year 2025 Award – Utah Business Trade Partner in Safety Excellence (Layton Construction) BZI is a proud member of and accredited by AISC, an organization that has recognized BZI with its top safety awards, the "Erector Award of Honor' and 'Safety Award of Merit.' CEO James Barlow serves on the Forbes Business Council and is a recipient of the prestigious Malcolm Baldrige Award. BZI's mission is to revolutionize the steel construction industry through innovation and team performance, while accelerating project delivery and setting new standards in safety and efficiency. About Energage Energage is an HR technology company on a mission to help organizations build and brand exceptional workplace cultures. We power the Top Workplaces employer recognition program and deliver actionable, research-backed employee survey insights that fuel professional growth and elevate employer brands. Our comprehensive talent experience platform combines cutting-edge tools, expert guidance, and built-in personalization to cultivate cultures that boost engagement, improve retention, attract top talent, and drive better business results. Learn more at and

Adios Ignites with Massive Launch Weekend - Millions in Distributor Commitments, 135M+ Impressions, and Surging Pre-Sales
Adios Ignites with Massive Launch Weekend - Millions in Distributor Commitments, 135M+ Impressions, and Surging Pre-Sales

Yahoo

timean hour ago

  • Yahoo

Adios Ignites with Massive Launch Weekend - Millions in Distributor Commitments, 135M+ Impressions, and Surging Pre-Sales

Backed by Manny Pacquiao and Cookies®, Adios Becomes One of the Hottest Beverage Debuts of the Year Ahead of August 15 Launch JACKSON, WY / / July 23, 2025 / Labor Smart Inc. (OTCID:LTNC), a Wyoming-based public company, is thrilled to announce a breakout launch weekend for its flagship tequila-based ready-to-drink (RTD) brand, Adios, which has already generated millions of dollars in wholesale commitments, over 135 million impressions, and surging pre-sale momentum at The launch was fueled by global legend Manny Pacquiao's return to the ring, which ended in a dramatic draw and attracted global media attention. As a central ambassador for Adios, Manny's presence helped catapult the brand into the cultural mainstream, while Cookies®, the iconic lifestyle brand founded by Berner, amplified the launch through its unmatched digital and retail network. Brandon Figueroa also notched a major win on the same card, reinforcing Adios' strong connection to combat sports and cultural relevance. "The response to Adios has been nothing short of explosive," said Brad Wyatt, CEO of LTNC. "We've already secured millions of dollars in wholesale commitments from distribution partners, and the online pre-sale at is tracking well above expectations. We're seeing real momentum-and it's only the beginning." Crafted with ultra-premium tequila, real fruit juice, and zero artificial additives, Adios is the result of a strategic partnership between LTNC, Cookies®, Casa Rica, and Flaviar. The official retail launch begins August 15 in California, with other U.S. and international markets to follow shortly. "The Adios launch was a cultural moment-and the perfect way to lead into what's next," said Tom Zarro, Chairman of the Board. "We're now preparing to bring Lock'd In into the spotlight in a way it's never seen before." Lock'd In: A Grassroots Favorite Poised for Breakout Lock'd In Hydrogen Water has been building steadily with a loyal customer base-especially among LTNC's long-term shareholders. While the brand has seen consistent sales since its initial launch, a major new deal now in the works is expected to mark the most significant milestone in the brand's history. Full details will be announced soon. About Labor Smart Inc. (LTNC)Labor Smart Inc. is a Wyoming-based public company focused on building and scaling culturally relevant beverage brands across the alcoholic, non-alcoholic, and wellness sectors. Its portfolio includes Adios Spirits, GoFast Energy, Lock'd In Hydrogen Water, and Xing Tea. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current expectations, estimates, and projections about the industry, management's beliefs, and assumptions made by management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict. Actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors. Investor Relations Contact: ir@ SOURCE: Labor Smart, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Yahoo

timean hour ago

  • Yahoo

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here. A selection of key takeaways includes: The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC. Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication. The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm. Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon PattonDirector of IR & Communicationjpatton@ Investor Relations for Oncolytics Mike MoyerLifeSci Advisors+1-617-308-4306mmoyer@ Media Contact for Oncolytics Owen BlaschakLifeSci Communicationsoblaschak@ Logo - View original content to download multimedia: SOURCE Oncolytics Biotech® Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store